Overview

A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Status:
Completed
Trial end date:
2019-06-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate clinical and laboratory safety of eribulin mesylate in treating participants with locally advanced or metastatic breast cancer, who have progressed after at least one regimen of chemotherapy which has included anthracycline and taxane therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Eisai Inc.